Treatment for knee osteoarthritis using 99Tc-MDP
99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis
This study is testing a new anti-inflammatory drug called 99Tc-MDP to see if it works better than celecoxib for people with knee osteoarthritis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT02993029 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of 99Tc-MDP, a patented anti-inflammatory drug, on patients suffering from knee osteoarthritis (OA) compared to the commonly used medication celecoxib. The study aims to address the increasing prevalence of knee OA, particularly among the aging population, and seeks to improve patient outcomes by potentially modifying the disease's progression. Participants will be evaluated based on specific criteria, including the severity of their OA as indicated by bone scans. The trial is conducted at Xinhua Hospital and the Tenth People's Hospital in Shanghai.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with painful knee osteoarthritis and a specific uptake value on bone scans.
Not a fit: Patients who have undergone knee joint replacement or have inflammatory arthritis or joint infections will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with knee osteoarthritis, potentially improving their quality of life.
How similar studies have performed: While 99Tc-MDP has been effective for rheumatoid arthritis, its application in knee osteoarthritis is novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants with painful osteoarthritis; 2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan; 3. Participants voluntarily participate in the trial, and signed the informed consent. Exclusion Criteria: 1. Knee joint replacement; 2. Inflammatory arthritis or joint infection of knee; 3. Nervous joint disease; 4. Fracture of joint; 5. Gout arthritis of the knee; 6. Traumatic arthritis.
Where this trial is running
Shanghai, Shanghai Municipality
- Department of Nuclear Medicine, Tenth People's Hospital of Tongji University — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Zhongwei Lv, MD — The 10th Hospital, Tongji University
- Study coordinator: Chao Ma, MD
- Email: mc_7419@hotmail.com
- Phone: +86-021-25078593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.